Table 1.
Patients’ demographic and clinical characteristics.
| Patient number | Age(years)/ gender |
Bone marrow plasma cells | M protein type |
Serum M protein quantity (g/L) |
Serum iFLC/dFLC (mg/L) | Hemoglobin (g/L) | Renal histology | eGFR (ml/min/1.73m2) | Proteinuria (g/24h) | UACR (mg/g•Cr) |
NT-proBNP (pg/ml) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01 | 52/male | 11% | IgG k | 7.1 | 1227.1/1206.8 | 155 | MIDD | 112.5 | 4.71 | 7858.2 | < 100 |
| 02 | 57/male | 2.0% | IgG λ | 4.1 | 47.1/7.8 | 123 | PGNMID | 66.0 | 7.02 | 2853.6 | < 100 |
| 03 | 46/male | 6.5% | IgG λ | 22.7 | 184.3/174.8 | 138 | AL | 117.6 | 4.3 | 2241.4 | < 100 |
| 04 | 58/female | 4.5% | λ | 1.0 | 1715.8/1709.9 | 110 | AL | 226.4 | 8.47 | 647.0 | 1200 |
| 05 | 60/male | 0.0% | IgG k | 6.4 | 21.0/6.9 | 95 | PGNMID | 73.0 | 1.94 | 1626.2 | < 100 |
| 06 | 46/male | 9.5% | IgG k and λ biclonal |
IgG k (3.6) | 90.7/72.4 | 120 | AL | 298.3 | 1.41 | 877.2 | < 100 |
| 07 | 70/male | 0.5% | IgG λ | 7.2 | 483.7/463.8 | 126 | AL | 81.9 | 3.1 | 3016.8 | < 100 |
| 08 | 51/male | 0.5% | Negative | 0.0 | 145.0/49.7 | 141 | LCPT | 75.4 | 1.1 | 141.8 | < 100 |
| 09 | 49/female | 4.5% | IgG k | 5.8 | 152.2/118.6 | 83 | LCDD | 19.6 | 2.9 | 2430.0 | < 100 |
| 10 | 52/female | 7.0% | IgG k | 6.1 | 742.8/707.5 | 63 | LCDD | 16.7 | 3.1 | 4002.5 | 18000 |
M-protein, Monoclonal immunoglobulin; iFLC, involvement of free light chain; dFLC, difference FLC; eGFR, estimated glomerular filtration rate; UACR, Urine albumin-to-creatinine ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MIDD, monoclonal immunoglobulin deposition disease; PGNMID, Proliferative glomerulonephritis with monoclonal immunoglobulin deposits; AL, light chain amyloidosis; LCPT, Light chain proximal tubulopathy; LCDD, light chain deposition disease.